FDA Expands Indication for Lutetium-177 PSMA-617 in PSMA-Positive mCRPC
The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer after androgen therapy.
Read More
Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.
Listen
Leronlimab Gets FDA Nod for Phase 2 Microsatellite-Stable CRC Trial
A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable metastatic colorectal cancer.
Juneja Explores AI’s Impact in Early Cancer Detection and Treatment
In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.
Pembrolizumab/XL888 Combination Shows Safety and Feasibility in Advanced CRC
Pembrolizumab and XL888 in advanced CRC showed manageable safety, though limited responses and potential immunomodulatory warrant further investigation.
Zongertinib Shows Antitumor Activity in Patients With HER2-Altered Tumors
The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive non–small cell lung cancer.
